- Frontage Europe has relocated its bioanalytical laboratory to a 2,500 square meter facility near Milan to consolidate services and improve efficiency.
- The site operates under GLP and GCP, adds Central Lab services, and expands analytical platforms and storage to support clinical studies.
Frontage Europe, a wholly owned subsidiary of Frontage Laboratories Inc., has relocated its bioanalytical laboratory to a consolidated 2,500 square meter facility close to Milan, Italy. The move is intended to increase operational efficiency and streamline processes by bringing services together at a single site.
The bioanalytical laboratory serves as a core element of the company’s services portfolio and is equipped for quantitative mass spectrometry, ligand-binding assays, and biomarker analysis. Platforms include LC-MS/MS, Meso Scale Discovery, Quanterix Simoa HD-X, and ELISA assays, with recent expansion through the addition of the Lumipulse G1200 instrument.
The facility operates under a Good Laboratory Practice quality system and complies with Good Clinical Practice to support clinical studies. Bioanalytical assay validation and sample analysis are conducted in line with ICH M10 regulatory guidance. The laboratory also provides pharmacokinetics expertise and scientific input for regulatory documentation, including investigator brochures and IND submissions.
To address client requirements, Frontage Europe has added Central Lab services, offering logistics and project management for clinical studies. The site’s location, approximately 25 km from Malpensa Airport, is intended to support sample logistics. The Central Lab offering is being strengthened through targeted investments in analytical and sample processing laboratories and expanded in-house storage capacity at −80°C and −20°C.
In addition, the company provides custom synthesis of radiolabeled and stable-labeled compounds and supports metabolism studies using high-resolution mass spectrometry. These services cover in vitro matrices and in vivo samples from both preclinical and clinical studies, extending the laboratory’s support across development stages.
